Every 10-Q that Alzamend Neuro, Inc. (ALZN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALZN filings page.
Alzamend Neuro, Inc. (ALZN) reported a net loss of $3.0 million for the three months ended July 31, 2026, slightly higher than the $2.7 million loss a year earlier, and it continues to generate no product revenue as its two drug candidates, AL001 and ALZN002, remain in clinical development.
Cash increased to $7.6 million from $0.7 million at April 30, 2026, driven by a $7.5 million first tranche of Series D Convertible Preferred Stock sold to Ault Lending and $0.7 million raised via an at-the-market common stock program, lifting stockholders’ equity to $5.8 million. Research and development expense declined 38% to $1.1 million as an earlier imaging study concluded, while general and administrative expense more than doubled to $1.9 million, largely on higher legal and professional fees. The company ended the quarter with working capital of $5.5 million but disclosed an accumulated deficit of $70.3 million, stated it expects continued losses, and concluded that these conditions raise substantial doubt about its ability to continue as a going concern, noting that additional financing will be required to sustain operations and advance its clinical programs.
Alzamend Neuro, Inc. reported a net loss of $2.2 million for the quarter and $5.9 million for the nine months ended January 31, 2026, with no product revenue as it advances two CNS drug candidates, AL001 and ALZN002.
Research and development expenses rose sharply to $1.3 million for the quarter and $3.2 million year‑to‑date, mainly from AL001 Phase II work with Massachusetts General Hospital. General and administrative expenses were $0.9 million for the quarter and $2.7 million for nine months, driven by legal fees, including litigation related to an ALZN002 CRO.
Cash was $2.7 million and working capital $1.8 million as of January 31, 2026, after using $5.3 million in operating cash flows and raising $4.0 million from Series C preferred stock. Management states there is “substantial doubt” about the company’s ability to continue as a going concern without additional financing and has launched a $3.0 million at‑the‑market equity program. The company also reports a continuing material weakness in internal control over financial reporting.
Alzamend Neuro, Inc. reported cash of $5,928,830 at July 31, 2025, up from $4,177,377 at April 30, 2025, and a net increase in cash of $1,672,214 for the period. The company recorded a net loss of $2.7 million for the three months ended July 31, 2025, and used $2.4 million in operating activities during the quarter. Management states the company expects to continue to incur net losses in the foreseeable future. As of the filing the company reported working capital of $4.9 million, an accumulated deficit of $61.2 million, and stockholders' equity of $5.3 million. The filing discloses that the company has historically financed operations primarily through issuances of equity and debt and details multiple preferred and common equity transactions and conversions completed during the period.